Can a targeted drug curb the devastating attacks of NMOSD?
NCT ID NCT07762872
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This study looks at whether giving satralizumab early during an attack of neuromyelitis optica spectrum disorder (NMOSD) can improve recovery and reduce long-term disability. Researchers will follow 50 adults with NMOSD who receive satralizumab as part of their routine care, tracking their disability, quality of life, and safety over six months. The goal is to see if this approach offers a more effective way to manage attacks and improve outcomes for patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- satralizumab
- What this could lead to
- If effective, early satralizumab treatment could reduce disability and improve recovery for people with NMOSD during attacks.
- What could go wrong
- This is a small, observational study without a comparison group, so results may not prove cause and effect. Satralizumab can have side effects, including infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDERS (NMOSD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xuanwu Hospital Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100053, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.